Fate Therapeutics
FATE
$1.28
Share price
-8.93%
Change (1 day)
-64.29%
Change (1 year)
Categories
Operating Margin for Fate Therapeutics (FATE)
Operating Margin as of June 2025 (TTM): -1,392.95%
According to Fate Therapeutics 's latest financial reports and stock price the company's current Operating Margin is -1,392.95%. At the end of 2024 the company had an Operating Margin of -1,434.52%.
Operating Margin history for Fate Therapeutics from 2013 to 2025
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2024 | -1,434.52% | 378.39% |
| 2023 | -299.86% | -6.36% |
| 2022 | -320.23% | -17.58% |
| 2021 | -388.56% | -4.64% |
| 2020 | -407.47% | -54.86% |
| 2019 | -902.59% | -34.08% |
| 2018 | -1,369.24% | 34.87% |
| 2017 | -1,015.20% | 40.42% |
| 2016 | -722.97% | -36.72% |
| 2015 | -1,142.41% | |
| 2013 | -2,069.82% | 301.86% |
| 2012 | -515.06% | -54.69% |
| 2011 | -1,136.75% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Sarepta Therapeutics
SRPT | -7.35% | -99.47% | 🇺🇸 USA |
 Becton Dickinson BDX | 8.06% | -100.58% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | 36.74% | -102.64% | 🇺🇸 USA |
 Avidity Biosciences RNA | -4,136.00% | 196.92% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | 20.63% | -101.48% | 🇺🇸 USA |
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.